NEW YORK (AP) — New data show sales of cholesterol blockbuster Lipitor plunged by half barely a week after the world's top-selling drug got its first U.S. generic competition.
That's despite a very aggressive effort by Lipitor maker Pfizer Inc. to keep patients on its pill, which once generated sales of $13 billion a year. Pfizer has been contracting with insurance plans to subsidize both patient copayments and costs for insurers, to keep their costs at or below what generic Lipitor would cost.
Miller Tabak analyst Les Funtleyder says the drop in the number of Lipitor prescriptions filled is not as great as he expected.
Continue Reading for Free
Register and gain access to:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
